Trials / Unknown
UnknownNCT03019276
A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
Phase I Study of Tolerance and Pharmacokinetics of TQ-B3101 in Patients With Advanced Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a reasonable regimen for subsequent research.
Detailed description
single arm, single or repeat dosing of TQ-B3101 on patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3101 | Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days . |
Timeline
- Start date
- 2017-07-05
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2017-01-12
- Last updated
- 2017-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03019276. Inclusion in this directory is not an endorsement.